• Last updated：2024-08-21
• Count Views：807

Since its establishment in 2006, the CDE has been providing quality services for various sectors of the industry, the academia, the government and the general public through a professional team with regulatory science expertise. The CDE aims to maximize the public health outcome based on balanced considerations of risk and benefit. As commissioned by the TFDA, the CDE performs various tasks, including implementing the Good Review Practice, enhancing quality management for the review of drugs and medical devices and assisting the TFDA in drafting regulations and guidance. Furthermore, the CDE plans to advance project-based services towards platform-based services by providing sponsors and research institutes with regulatory science advisory services in the early phases of the development of innovative drugs and medical devices. The CDE’s HTA team works closely with the NHIA to perfect the health care system in Taiwan. The CDE maintains professional connections with other regulatory agencies in major countries so as to facilitate the exchanges of experiences and information of regulatory science. With all these efforts, the CDE continues to be an instrumental partner of the TFDA and the NHIA in protecting the public health in Taiwan.